Fat-resolving

"Fat-resolving" is not a canonical biological target but a descriptive term used in medical aesthetics and metabolic research to denote agents or processes that reduce localized or systemic adipose tissue. In the context of non-surgical body contouring, it typically refers to injectable lipolytic agents like deoxycholic acid, which acts as a detergent to physically disrupt adipocyte cell membranes, leading to permanent cell death and fat removal (Skin Heal, 2024; Medisilk, 2024). In the broader context of metabolic disease research, the term describes therapies that "resolve" fat accumulation by targeting appetite, lipid absorption, or energy expenditure (PMC, 2011). Additionally, "fat-resolving" can relate to "Specialized Pro-resolving Mediators" (SPMs) such as resolvins, which are fat-derived signaling molecules that bind to receptors like FPR2 or ChemR23 to coordinate the resolution of inflammation and promote tissue homeostasis (NIH, 2020; PubMed Central). Consequently, while the term itself describes a therapeutic goal, the functional targets include the adipocyte cell membrane and various metabolic and inflammatory signaling receptors. Modern pharmaceutical approaches often utilize GLP-1 receptor agonists to achieve systemic fat resolution by improving metabolic parameters and inducing weight loss (Fatty Liver Alliance, 2025). Safety profiles for these treatments vary from localized injection site reactions to systemic gastrointestinal and hepatic considerations (NIH, 2020).

Other names

Fat-dissolvingLipolysisAdipolysisMesotherapyLipo-dissolvingPro-resolving lipid mediators

Includes adipocyte cell membrane disruption via detergent action (e.g., deoxycholic acid), inhibition of gastric and pancreatic lipases (e.g., orlistat), and activation of GLP-1 receptors to promote metabolic health and satiety (e.g., semaglutide). Additionally, it may involve the activation of pro-resolving receptors such as FPR2 and ChemR23 by lipid mediators.